MediWound Ltd. MDWD
13.54 USD -0.07 (-0.51%)
Regular-session close
13.54 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
13.35 Day range 13.67
11.80 52-week range 19.70
- YTD
- -26.65%
- 1 year
- -24.19%
News
globenewswire.com MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 MediWound to Host Virtual KOL Event on EscharEx ® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 Leading wound care experts to discuss Phase II clinical evidence, the pivotal…
marketbeat.com What MediWound (MDWD) Said on Its Q3 Earnings Call MediWound NASDAQ: MDWD reported lower third-quarter revenue and a wider net loss as it increased spending on its late-stage EscharEx trial, while executives said manufacturing constraints continue to…
seekingalpha.com MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript
benzinga.com MediWound Q3 2026 Earnings Call Transcript MediWound (NASDAQ:MDWD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
zacks.com MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates MediWound (MDWD) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.24 per share a year ago.benzinga.com CORRECTION: MediWound Q3 EPS $(0.65) Beats $(0.71) Estimate, Sales $3.600M Miss $6.728M Estimate MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.71) by 8.45 percent. This is a 170.83 percent decrease over losses of $(0.24)…
benzinga.com MediWound Q3 EPS $(0.46) Beats $(0.71) Estimate, Sales $3.600M Miss $6.728M Estimate MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.71) by 35.21 percent. This is a 91.67 percent decrease over losses of $(0.24)…
globenewswire.com MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027benzinga.com MediWound Announces $15M Bought Deal Offering Of 1.2M Shares At $12.50/Share The closing of the offering is expected to occur on or about November 5, 2026, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the sole book-running manager…
